Search Results for “cancer” – Page 151 – media

Why AstraZeneca’s New Drug Strategy Seems to be Bearing Fruit

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
- Source: china-pharmacy
- 484
- February 7, 2018
AstraZeneca New Drug Strategy
Insightec closes $150m Series E

HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
- Source: drugdu
- 510
- February 6, 2018
Market Views MRgFUS non-invasive treatments
Nicotine in E-cigarettes damages DNA, mouse study suggests

The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
- Source: medicalxpress
- 603
- February 6, 2018
cancer DNA e-cigarettes nicotine Researches
Why healthcare cybersecurity spending will exceed $65B over the next 5 years

Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
- Source: CSO Online
- 553
- February 6, 2018
cybersecurity digital health Market Views
GSK China partners with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience

GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system. The system will include online disease education and consultation, online HCP appointment booking, and deliver convenient online-to-offline (O2O) end-to-end service for users. Moreover, community healthcare service centres nationwide can utilise this platform to manage vaccination enquiries and requests. This will help enhance efficiency at the centres and help reduce costs and workload, thus optimising public healthcare institutions’s resources. By year-end, the platform is expected to cover 1500 community healthcare service centres in more than one hundred cities nationwide, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing and Wuhan.
- Source: gsk-china
- 570
- February 5, 2018
adult vaccination service system Ali Health GSK China health
NHS plans to be first to eliminate hepatitis C

NHS England has laid out plans for England to become the first country to eliminate hepatitis C, at least five years earlier than the World Health Organisation(WHO)’s target date of 2030.
- Source: pharmatimes
- 872
- February 2, 2018
hepatitis C NHS polices WHO
Augmented Reality Helps Surgeons ‘See Through’ Tissue & Reconnect Blood Vessels

Surgeons use Microsoft HoloLens headsets while operating on patients undergoing reconstructive lower limb surgery.
- Source: ODT
- 579
- February 2, 2018
augmented reality medical device Researches surgery
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 740
- February 1, 2018
Company Insight digital health EHR NICE
Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
- Source: Biospace
- 455
- February 1, 2018
Cascadian HER2 Market Views merger-and-acquisition
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 599
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.